Department of Hematology and Oncology, Wilhelmina Children's Hospital, University Medical Center Utrecht Utrecht, Netherlands.
Front Oncol. 2013 Apr 2;3:68. doi: 10.3389/fonc.2013.00068. eCollection 2013.
B-cell lymphoma in children accounts for about 10% of all pediatric malignancies. Chemotherapy has been very successful leading to an over-all 5-year survival between 80 and 90% depending on lymphoma type and extent of disease. Therapeutic toxicity remains high calling for better targeted and thus less toxic therapies. Therapeutic antibodies have become a standard element of B-cell lymphoma therapy in adults. Clinical experience in pediatric lymphoma patients is still very limited. This review outlines the rationale for antibody treatment of B-cell lymphomas in children and describes potential target structures on B-cell lymphoma cells. It summarizes the clinical experience of antibody therapy of B-cell lymphoma in children and gives an outlook on new developments and challenges for antibody therapy of pediatric B-cell lymphoma.
儿童 B 细胞淋巴瘤约占所有儿科恶性肿瘤的 10%。化疗非常成功，根据淋巴瘤类型和疾病程度的不同，总 5 年生存率在 80%至 90%之间。治疗毒性仍然很高，需要更好的靶向治疗，从而降低毒性。治疗性抗体已成为成人 B 细胞淋巴瘤治疗的标准组成部分。儿科淋巴瘤患者的临床经验仍然非常有限。本文综述了抗体治疗儿童 B 细胞淋巴瘤的原理，并描述了 B 细胞淋巴瘤细胞上的潜在靶结构。总结了抗体治疗儿童 B 细胞淋巴瘤的临床经验，并展望了儿童 B 细胞淋巴瘤抗体治疗的新进展和挑战。
